Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

245 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Schmidt-Erfurth U, Lang GE, Holz FG, Schlingemann RO, Lanzetta P, Massin P, Gerstner O, Bouazza AS, Shen H, Osborne A, Mitchell P; RESTORE Extension Study Group. Schmidt-Erfurth U, et al. Among authors: lang ge. Ophthalmology. 2014 May;121(5):1045-53. doi: 10.1016/j.ophtha.2013.11.041. Epub 2014 Feb 1. Ophthalmology. 2014. PMID: 24491642 Free article. Clinical Trial.
The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema.
Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, Sutter F, Simader C, Burian G, Gerstner O, Weichselberger A; RESTORE study group. Mitchell P, et al. Among authors: lang ge. Ophthalmology. 2011 Apr;118(4):615-25. doi: 10.1016/j.ophtha.2011.01.031. Ophthalmology. 2011. PMID: 21459215 Free article. Clinical Trial.
Diabetic macular edema.
Lang GE. Lang GE. Ophthalmologica. 2012;227 Suppl 1:21-9. doi: 10.1159/000337156. Epub 2012 Apr 24. Ophthalmologica. 2012. PMID: 22517122 Review.
Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study.
Hoerauf H, Feltgen N, Weiss C, Paulus EM, Schmitz-Valckenberg S, Pielen A, Puri P, Berk H, Eter N, Wiedemann P, Lang GE, Rehak M, Wolf A, Bertelmann T, Hattenbach LO; COMRADE-C Study Group. Hoerauf H, et al. Among authors: lang ge. Am J Ophthalmol. 2016 Sep;169:258-267. doi: 10.1016/j.ajo.2016.04.020. Epub 2016 May 7. Am J Ophthalmol. 2016. PMID: 27163237 Clinical Trial.
Comparison of ranibizumab versus dexamethasone for macular oedema following retinal vein occlusion: 1-year results of the COMRADE extension study.
Feltgen N, Hattenbach LO, Bertelmann T, Callizo J, Rehak M, Wolf A, Berk H, Eter N, Lang GE, Pielen A, Schmitz-Valckenberg S, Quiering C, Rose U, Hoerauf H; COMRADE Study Group. Feltgen N, et al. Among authors: lang ge. Acta Ophthalmol. 2018 Dec;96(8):e933-e941. doi: 10.1111/aos.13770. Epub 2018 May 31. Acta Ophthalmol. 2018. PMID: 29855153 Free article. Clinical Trial.
Observational outcomes in proliferative diabetic retinopathy patients following treatment with ranibizumab, panretinal laser photocoagulation or combination therapy - The non-interventional second year follow-up to the PRIDE study.
Lang GE, Stahl A, Voegeler J, Quiering C, Zaremba L, Lorenz K, Spital G, Liakopoulos S. Lang GE, et al. Acta Ophthalmol. 2022 Mar;100(2):e578-e587. doi: 10.1111/aos.14907. Epub 2021 Jun 14. Acta Ophthalmol. 2022. PMID: 34121335 Free article.
245 results